Table 1.
Baseline demographic and clinical characteristics.
| Characteristic | Patients, no. (%) | |
|---|---|---|
| Chemotherapy doublet plus targeted therapy by RAS* status (n = 126) | Chemotherapy triplet plus targeted therapy by RAS* status (n = 130) | |
| Age, median (range) | 61 (29–75) | 60 (27–78) |
| Sex | ||
| Male | 82 (65.1) | 81 (62.3) |
| Female | 44 (34.9) | 49 (37.7) |
| ECOG performance status | ||
| 0 | 84 (66.7) | 82 (64.1) |
| 1 | 42 (33.3) | 46 (35.9) |
| Primary tumour location | ||
| Right colon | 32 (25.4) | 28 (21.7) |
| Left colon | 58 (46) | 63 (48.8) |
| Rectum | 33 (26.2) | 34 (26.4) |
| Multiple | 3 (2.4) | 4 (3.1) |
| Unknown | 0 | 1 |
| Surgery of the primary tumour | 40 (31.7) | 43 (33.1) |
| Synchronous metastases | 111 (88.1) | 117 (90.0) |
| Lung metastases | 16 (12.7) | 14 (11.2) |
| Non-resectability reason | ||
| Technical | 90 (71.4) | 92 (72.4) |
| Oncological | 23 (18.3) | 27 (21.3) |
| Both | 13 (10.3) | 8 (6.3) |
| Unknown | 0 | 3 |
| Median CEA (ng/mL) | 96 | 58.7 |
| Median leucocyte count (109/L) | 9.1 | 6.8 |
ECOG Eastern Cooperative Oncology Group, CEA carcinoembryonic antigen.
RAS* is KRAS/NRAS exon 2, exon 3, exon 4 genotyping.